The Maharashtra Food and Drug Administration cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s C&F facility in Wadki, Pune, effective August 27.
Regulators seized Reactin Plus stock worth ₹11.19 lakh after finding unauthorised promotional text on packaging and irregularities in storage and distribution records.
The FDA inspection revealed medicines were stored directly on the floor and identified significant discrepancies between physical and computerised stock records at the facility.